Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus GG

What does the research say about Lactobacillus rhamnosus GG?

3 health outcomes synthesised

Lactobacillus rhamnosus GG has been studied across 3 health outcomes, with the strongest evidence supporting its role in reducing diarrhea rate (moderate evidence strength from 3 studies). Research primarily involves children with antibiotic-associated diarrhea or acute gastroenteritis, with doses not consistently reported across studies. Notably, evidence for other outcomes—reducing diarrhea duration and improving quality of life—is weaker and more mixed.

Strongest evidence: The outcome with the strongest backing is Reduced Diarrhea Rate, supported by moderate evidence from 3 studies, all of which reported beneficial effects. The predominant effect size was large, with two meta-analyses and one RCT showing reductions in antibiotic-associated diarrhea risk (from 22.4% to 12.3%) and rotavirus diarrhea recurrence (25% vs. 46%). Effective doses were not reported across these studies, limiting dose-specific conclusions. Populations included children and adults with antibiotic-associated diarrhea and children with acute gastroenteritis (including rotavirus).

Mixed or weaker evidence: Two outcomes have low evidence strength. For Reduced Duration of Diarrhea, 2 of 3 studies reported benefit, but the largest, highest-quality RCT (n=943) found no significant difference. For Improved Health-related Quality of Life, 2 of 3 studies showed benefit (effect sizes small to moderate), but a pilot RCT in ulcerative colitis patients found no added benefit over placebo, suggesting population-specific effects.

Effective dose patterns: Across outcomes, a dose of ≥10^10 CFU per day (e.g., 1×10^10 CFU twice daily) was identified only for reducing diarrhea duration. For all other outcomes, effective doses were not consistently reported or specified, preventing generalized dose recommendations.

Population insights: The strongest evidence comes from children, particularly those with antibiotic-associated diarrhea or acute gastroenteritis. For quality of life, beneficial effects were seen in children and adolescents with ADHD, but not in adults with ulcerative colitis, indicating the effect may be population-specific.

Notable caveats: The evidence base is small (only 3 studies per outcome), so all conclusions should be considered preliminary. Clinical literature for diarrhea outcomes is subject to publication bias. One meta-analysis noted low quality of evidence for antibiotic-associated diarrhea, and some studies did not report doses or forms of L. rhamnosus GG, limiting reproducibility and dose-specific recommendations.

Frequently asked

  • What is Lactobacillus rhamnosus GG good for according to research?
    Research shows Lactobacillus rhamnosus GG is most strongly associated with reducing diarrhea rate in children and adults with antibiotic-associated diarrhea or acute gastroenteritis (moderate evidence from 3 studies, all beneficial). It may also help reduce diarrhea duration and improve quality of life, but evidence for these outcomes is weaker and more mixed.
  • What dose of Lactobacillus rhamnosus GG is typically used in studies?
    An effective dose of at least 10^10 CFU per day (e.g., 1×10^10 CFU twice daily) was used in studies on reducing diarrhea duration. However, doses were not reported for studies on diarrhea rate or quality of life, so dose-specific recommendations across outcomes are limited.
  • Who benefits most from Lactobacillus rhamnosus GG?
    The strongest evidence is in children, particularly those with antibiotic-associated diarrhea or acute gastroenteritis (including rotavirus). For quality of life, beneficial effects were seen in children and adolescents with ADHD, but not in adults with ulcerative colitis, suggesting the effect may be population-specific.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus GG?
    Yes, the evidence base is small (only 3 studies per outcome), so conclusions are preliminary. Clinical literature on diarrhea outcomes may be subject to publication bias. One meta-analysis noted low quality of evidence for antibiotic-associated diarrhea, and some studies did not report doses or forms, limiting reproducibility.
  • Does Lactobacillus rhamnosus GG help reduce diarrhea rate?
    Moderate evidence from 3 studies suggests yes, particularly for antibiotic-associated diarrhea and rotavirus diarrhea in children. Two meta-analyses and one RCT found large reductions in diarrhea risk (e.g., from 22.4% to 12.3%) and recurrence (25% vs. 46%).
  • Does Lactobacillus rhamnosus GG help improve quality of life?
    Low evidence from 3 studies shows mixed results. Two studies found small to moderate benefits in children with ADHD, but a pilot RCT in adults with ulcerative colitis found no added benefit over placebo, indicating effects may be population-specific.

Safety profile

10 studies reporting safety data2 serious adverse events

Across 10 clinical studies, no specific adverse events were reported at significantly increased rates in the Lactobacillus rhamnosus GG group compared to control. Two quantitative assessments from one study found no significant differences in mortality (42.8% vs 68.7%, p=0.27) or bacterial cholangitis (21% vs 50%, p=0.14). The probiotic was described as generally well tolerated in all 10 studies, though rare serious adverse events such as bacteremia or antibiotic resistance gene transfer have been flagged in immunocompromised populations. Overall, the safety profile appears favorable, but evidence is largely based on tolerability statements rather than rigorous safety endpoints.

Caveats: Most studies were small or not primarily designed to assess safety, limiting detection of rare adverse events. Methodological heterogeneity and short follow-up durations (e.g., 2 years in one study) reduce generalizability. Safety in immunocompromised or critically ill individuals requires individualized risk–benefit assessment, as potential serious events have been noted in those populations.

Most-studied combinations with Lactobacillus rhamnosus GG

most supplement research is combination research
Also studied with:Saccharomyces boulardii (2), Lactobacillus reuteri DSM 17938 (4), Vitamin D (3), saccharomyces boulardii (2)

  • Oral Health Probiotics

    By NatureWise

    4.7 (642 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $31.54
    		In
    Vitacost
    $26.99
    		In
    Vitamin Shoppe
    $-
    		Out

  • Fortify, Women's Probiotic + Prebiotics, Everyday Care, 30 Billion

    By Nature's Way

    4.7 (557 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $19.19
    		In
    Vitacost
    $19.69
    		In
    Vitamin Shoppe
    $19.99
    		In

  • Prenatal Probiotic

    By LoveBug Probiotics

    4.8 (678 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $24.95
    		In
    Vitacost
    $-
    		Out
    Vitamin Shoppe
    $-
    		Out

  • Teen Clearface Vitamins

    By Codeage

    4.7 (402 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $27.99
    		In
    Vitacost
    $27.99
    		In
    Vitamin Shoppe
    $27.99
    		In

  • Probiotics

    By Culturelle

    4.6 (2.1K reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $25.65
    		In
    Vitacost
    $22.29
    		In
    Vitamin Shoppe
    $-
    		Out

  • Fortify

    By Nature's Way

    4.6 (268 reviews)
    In Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $17.27
    		In
    Vitacost
    $-
    		Out
    Vitamin Shoppe
    $-
    		Out
Back to top